O
Oliver P. Flint
Researcher at Bristol-Myers Squibb
Publications - 46
Citations - 2085
Oliver P. Flint is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Toxicity & Cell culture. The author has an hindex of 18, co-authored 46 publications receiving 1975 citations. Previous affiliations of Oliver P. Flint include Second Military Medical University.
Papers
More filters
Journal ArticleDOI
Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
Wei Meng,Bruce A. Ellsworth,Alexandra A. Nirschl,P.J. McCann,Manorama Patel,Ravindar N. Girotra,Gang Wu,Philip M. Sher,Eamonn P. Morrison,Scott A. Biller,Robert Zahler,Prashant P. Deshpande,Annie Pullockaran,Deborah Hagan,Nathan Morgan,Joseph R. Taylor,Mary T. Obermeier,William G. Humphreys,Ashish Khanna,Lorell Discenza,James G. Robertson,Aiying Wang,Songping Han,John R. Wetterau,Evan B. Janovitz,Oliver P. Flint,Jean M. Whaley,William N. Washburn +27 more
TL;DR: The C-aryl glucoside 6 (dapagliflozin) was identified as a potent and selective hSGLT2 inhibitor which reduced blood glucose levels in a dose-dependent manner by as much as 55% in hyperglycemic streptozotocin (STZ) rats.
Journal ArticleDOI
Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically.
TL;DR: Both glucose uptake in vitro and clinical insulin sensitivity in healthy volunteers demonstrate differential effects on glucose metabolism by the combination PI atazanavir/ritonavir and lopinavIR/rit onavir.
Journal ArticleDOI
Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro
TL;DR: Results indicate that depletion of metabolites of geranylgeranyl pyrophosphate, and not inhibition of cholesterol synthesis, is the primary cause of HMG CoA reductase-induced myotoxicity.
Journal ArticleDOI
In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes.
Barbara A. Masters,M.J. Palmoski,Oliver P. Flint,Richard E. Gregg,D Wang-Iverson,Stephen K. Durham +5 more
TL;DR: Results indicate that pravastatin is less myotoxic than lovastatin or simvastatin in this in vitro system using neonatal rat skeletal muscle cells, and this differential toxicity is correlated with the selective decrease in inhibition of HMG CoA reductase by pravASTatin in nonhepatic tissues.
Journal ArticleDOI
Developing High-Fidelity Hepatotoxicity Models From Pluripotent Stem Cells
Claire N. Medine,Baltasar Lucendo-Villarin,C. W. Storck,Faye Wang,Dagmara Szkolnicka,Ferdous Khan,Salvatore Pernagallo,James R M Black,Howard M. Marriage,James A. Ross,Mark Bradley,John P. Iredale,Oliver P. Flint,David C. Hay +13 more
TL;DR: It is reported that pluripotent stem cell‐derived hepatocytes will model toxicity predictably and in a manner comparable to current gold standard assays, representing a major advance in the field.